Core Insights - GoodRx Holdings, Inc. reported revenue of $200.61 million for the quarter ended June 2024, reflecting a year-over-year increase of 5.8% [1] - The earnings per share (EPS) for the same period was $0.08, compared to $0.07 a year ago, with an EPS surprise of -11.11% against a consensus estimate of $0.09 [1] Revenue Breakdown - Revenue from prescription transactions was $146.70 million, exceeding the estimated $146.29 million, marking a year-over-year increase of 7.5% [5] - Revenue from other sources was $5.40 million, slightly above the estimated $5.35 million, representing a year-over-year change of 10.2% [6] - Revenue from Pharma Manufacturer Solutions was $26.50 million, below the estimated $27.48 million, but still showing a year-over-year increase of 9.1% [7] - Subscription revenue was reported at $22 million, surpassing the estimated $21.17 million, but reflecting a year-over-year decline of 8% [8] Consumer Metrics - Monthly Active Consumers were reported at 7 million, matching the average estimate from three analysts [3] - Total subscribers were reported at 696, falling short of the two-analyst average estimate of 763 [4] Stock Performance - GoodRx shares have returned +7.8% over the past month, contrasting with a -6.5% change in the Zacks S&P 500 composite [8] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [8]

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%. Over the last four quarters, th ...

Group 1 - The upcoming report from GoodRx Holdings, Inc. (GDRX) is expected to show quarterly earnings of $0.09 per share, reflecting a 28.6% increase year over year [1] - Analysts forecast revenues of $200.68 million for the quarter, indicating a 5.8% year-over-year growth [1] - There has been no revision in the consensus EPS estimate for the quarter over the past 30 days, suggesting stability in analyst projections [1] Group 2 - Analysts estimate 'Revenue- Prescription transactions' at $146.29 million, representing a 7.2% increase from the previous year [4] - The consensus estimate for 'Revenue- Other' is $5.35 million, indicating a 9.2% increase from the prior-year quarter [4] - 'Revenue- Pharma Manufacturer Solutions' is projected to reach $27.48 million, reflecting a 13.1% increase year over year [4] Group 3 - The average prediction for 'Revenue- Subscription' is $21.17 million, which shows an 11.4% decrease compared to the year-ago quarter [5] - GoodRx shares have increased by 0.9% over the past month, contrasting with the Zacks S&P 500 composite's decline of 6.7% [5] - GDRX holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [5]

Core Viewpoint - GoodRx is facing significant industry headwinds and needs to double its market growth to support its current price target, which is challenging given its recent performance and market conditions [35][38]. Financial Performance - GoodRx is expected to report Q2 2024 revenue of approximately $200 million, reflecting a year-over-year increase of about 5% from $189.7 million in Q2 2023 [4]. - For FY 2024, revenue is projected to be around $800 million, up from $750.3 million in FY 2023, indicating a growth rate of approximately 7% to 8% [4]. - The company has struggled with cost growth outpacing revenue, necessitating a growth rate of over 10% to justify its stock price [7]. Market Position and Challenges - GoodRx currently holds only a 2% market share in its core business, indicating limited traction in a competitive landscape [9]. - The pharmaceutical industry is expected to grow at a compound annual growth rate (CAGR) of 6.15%, and GoodRx's growth is forecasted to align with this market growth, suggesting a lack of competitive advantage [25][26]. - The company has seen a 10% year-over-year increase in monthly active consumers, but this has been offset by a decline in subscription plans, which are crucial for stability [32]. Guidance and Valuation - Management's guidance suggests a high-end growth rate of 12%, but even this would only yield a minimal 4% upside based on discounted cash flow (DCF) analysis [35]. - The average price target for GoodRx is set at $7.50, indicating a potential downside of 13% from current pricing [3][35]. - Wall Street's price target has increased to $9.60, but this remains below the high-end of the analyst's expectations [16]. Strategic Initiatives - There is potential upside if GoodRx can secure major corporate or insurance partnerships, similar to its deal with Kroger, which could provide a steady customer base [1]. - Management has outlined several initiatives, including GLP-1, that are not fully accounted for in current guidance, but these are seen as necessary to address growth gaps [9].

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordab ...

Source: JPstock / Shutterstock.com A pending or ongoing lawsuit isn't always a reliable indicator of stocks to sell, but, in many cases, investors should take litigation as a sign to dig beneath the surface. Source: II.studio / Shutterstock.com Still, these stocks to sell combine the worst of both worlds: They're facing ongoing lawsuits, and in each of the three cases, the stock itself is a stinker. GoodRx (NASDAQ:GDRX) is facing a fresh lawsuit claiming the company misrepresented Kroger's (NYSE:KR) total c ...

The cost of prescription medications in the U.S. has increased by 37% since 2014, far surpassing the rate of inflation, according to data from drug savings company GoodRx. On average, Americans pay 2 to 3 times more for prescription drugs than consumers in other developed countries, according to the White House. — CNBC's Annika Kim Constantino contributed to this report. It's a dynamic GoodRx deems "the big pinch." High medication costs are coupled with reduced insurance coverage. Analyzing coverage for ove ...

GoodRx aims to give consumers a better handle on prescription affordability. High costs are a barrier for consumers seeking all sorts of healthcare beyond prescription drugs. In some cases, costs may have nothing to do with the medical field. "A multitude of health-related issues can cascade from there," PYMNTS reported this week. "Women who lack reliable transportation are 17% less likely to get the preventive medical care they need. Compared to those with access to transportation, they are also 78% more l ...

CONTACT US HERE: WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of ...

RADNOR, Pa., June 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was fi ...